Cristescu et al. showed that a combined stratification of high tumor mutational burden plus high T-cell inflamed gene expression profiles in melanomas and head and neck squamous cell carcinoma patients, improved the identification of responders and non-responders to anti-PD-1 therapy [426,427]. This evidence concerns the gene PDCD1 and melanoma.